Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan
The contract of this time has been made possible because Novartis Pharma, which aims to further increase growth of Diovan with a superior effect in the ARB market where competition is intensifying, and Mochida Pharmaceutical, which desires to provide additional strengths to its business foundation in the cardiovascular area that is a focused area of the company, had a common purpose.
"We are very pleased that we could build a partnership with Mochida Pharmaceutical, a company that is continuing to grow in the cardiovascular area through products such as Atelec and Epadel," says Noriyuki Baba, President, Novartis Pharma K.K. "We look forward to giving additional support to hypertensive patients by providing further information to medical professions to support the efficacy and safety of Diovan."
Naoyuki Mochida, President, Mochida Pharmaceutical Co., Ltd., said, "Novartis gave high marks to our company's scientific information service capabilities, and as a result selected Mochida as a co-promotion partner for Diovan, the No. 1 product in terms of sales in the ARB market. For 40 million hypertensive patients, we are determined to continue supplying information about Diovan and Atelec, our calcium channel blocking agent, quickly and extensively to medical professionals."
By co-operating in this way, the two companies will be able to provide Japanese clinicians with adequate information and comprehensive data to help establish Diovan's clinical profile as a therapy for high blood pressure.
Diovan is a drug synthesized and developed by Novartis, based in Switzerland, that has been engaged in research into the renin-angiotensin system from an early stage. Diovan works by selectively blocking the AT1 receptors that are involved in blood pressure elevation. Diovan has been approved as the first-line treatment for high blood pressure in around 100 countries. In Japan, when it was launched in 2000, Diovan has been widely adopted by physicians, reflecting the extensive evidence from a large-scale clinical trial program demonstrating its superior blood pressure lowering action and cardiovascular protective effect.
About Mochida Pharmaceutical Co., Ltd.
Since its foundation, Mochida Pharmaceutical has made effort in the R&D of original pharmaceuticals and is now focused on 4 important areas: cardiovascular, obstetrics and gynecology, dermatology and emergency care. The company's major products include Atelec, a long-acting calcium channel blocker and Epadel, a treatment for hyperlipidemia. Also, as a comprehensive group of healthcare-related companies in fields of medical devices, healthcare and drug manufacturing, it is making a wide-ranging contribution to medicine and health areas. For a fiscal year ended March 2006, the company's net income reached 4,900 million yen on net sales of 70.6 billion yen. The company employs approximately 1,800 people For more information, please visit http://www.mochida.co.jp/
About Novartis Pharma K.K.
Novartis Pharma K.K. is a Japanese subsidiary of the pharmaceutical division of Novartis AG, a world leader in healthcare. In 2006, the Group's businesses achieved net sales of USD 37.0 billion(approximately JPY 4294.3 billion). and net income of USD 7.2 billion (approximately JPY 835.4 billion). Approximately USD5.4 billion (approximately JPY 620.5 billion) was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.co.jp/
Novartis Pharma K.K. Corporate Communications Group Tel +81-3-3797-8027 Fax +81-3-3797-4367 E-mail: firstname.lastname@example.org Mochida Pharmaceutical Co., Ltd. Public Relations Tel +81-3-3225-6303 Fax +81-3-3225-6315 E-mail: webmaster @mochida.co.jp
Posted: January 2007